Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Revenue (2022 - 2025)

Historic Revenue for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to $32.5 million.

  • ARS Pharmaceuticals' Revenue rose 147161.51% to $32.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.8 million, marking a year-over-year increase of 545965.73%. This contributed to the annual value of $89.1 million for FY2024, which is 29706333.33% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Revenue of $32.5 million as of Q3 2025, which was up 147161.51% from $15.7 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Revenue high stood at $86.6 million for Q4 2024, and its period low was $10000.0 during Q2 2023.
  • Over the past 4 years, ARS Pharmaceuticals' median Revenue value was $663000.0 (recorded in 2022), while the average stood at $13.3 million.
  • Its Revenue has fluctuated over the past 5 years, first tumbled by 9784.48% in 2023, then soared by 490000.0% in 2024.
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' Revenue stood at $189000.0 in 2022, then crashed by 94.71% to $10000.0 in 2023, then surged by 865710.0% to $86.6 million in 2024, then plummeted by 62.46% to $32.5 million in 2025.
  • Its last three reported values are $32.5 million in Q3 2025, $15.7 million for Q2 2025, and $8.0 million during Q1 2025.